UPDATE: Agile Therapeutics Q2 Adj $(3.10) Beats $(3.48) Estimate, Sales $5.50M Beat $4.68M Estimate
Portfolio Pulse from Benzinga Newsdesk
Agile Therapeutics (NASDAQ:AGRX) reported Q2 losses of $(3.10) per share, beating the analyst consensus estimate of $(3.48) by 10.92%. This is a 97.71% increase over losses from the same period last year. The company also reported quarterly sales of $5.50 million, beating the analyst consensus estimate of $4.68 million by 17.59%, a 158.84% increase over sales from the same period last year.
August 09, 2023 | 12:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Agile Therapeutics reported better than expected Q2 results, with losses and sales beating analyst estimates.
Agile Therapeutics reported better than expected Q2 results, with both losses and sales beating analyst estimates. This could lead to increased investor confidence and a potential positive impact on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100